Severe oral mucositis relating to pain and worse oral condition among patients with solid tumors undergoing treatment with FOLFIRI and 5-FU
a retrospective study
Palavras-chave:
Stomatitis, Dental service, hospital, Drug therapy, Oral health, Oral medicine, Pathology, oralResumo
BACKGROUND: There is a need for studies that correlate the severity of oral mucositis (OM) with chemotherapy protocols, transient myelosuppression and oral health. OBJECTIVE: To analyze the severity of OM among individuals with solid tumors during hospitalization and its correlation with the type of chemotherapy, myelosuppression and oral health condition. DESIGN AND SETTING: Retrospective study at a public hospital in Bauru, state of São Paulo, Brazil, that is a regional referral center. METHODS: Individuals diagnosed with solid malignant tumors who received chemotherapy during hospitalization for completion of the antineoplastic treatment cycle or who presented complications resulting from this were assessed. RESULTS: Twenty-eight individuals (24.3%) manifested some degree of OM. The most prevalent degrees of OM according to the World Health Organization (WHO) and modified WHO classification were grades 2 (11.3%) and 5 (4.3%), respectively. It was observed that the higher the OM-WHO (P < 0.001; r = 0.306) and modified OM-WHO (P < 0.001; r = 0.295) classifications were, the greater the oral pain reported by the individuals was. Presence of mucositis in the upper lip and buccal mucosa contributed to increased severity of OM and worsening of swallowing during hospitalization. Thus, severe OM was associated with use of the FOLFIRI protocol (folinic acid, fluorouracil and irinotecan). CONCLUSION: Individuals with tumors who presented severe OM had greater severity of oral pain and worse oral health. Use of the FOLFIRI protocol was associated with higher prevalence of severe OM, while use of 5-fluorouracil (5-FU) was correlated with worse oral condition.
Downloads
Referências
Curra M, Soares Junior LAV, Martins MD, Santos PSDS. Chemotherapy protocols and incidence of oral mucositis. An integrative review. Einstein (Sao Paulo). 2018;16(1):eRW4007. PMID: 29694618; https://doi.org/10.1590/s1679-45082018rw4007
Kusial A, Jereczek-Fossa BA, Cichońska D, Alterio D. Oncological-therapy related oral mucositis as an interdisciplinary problem – literature review. Int J Environ Res Public Health. 2020;17(7):2464. PMID: 32260309; https://doi.org/10.3390/ijerph17072464
Villa A, Sonis ST. Mucositis: pathobiology and management. Curr Opin Oncol (Philadelphia). 2015;27(3):159-64. PMID: 25774860; https://doi.org/10.1097/CCO.0000000000000180
Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys (New York). 2007;68(4):1110-20. PMID: 17398022; https://doi.org/10.1016/j.ijrobp.2007.01.053
Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am. 2014;58(2):341-9. PMID: 24655526; https://doi.org/10.1016/j.cden.2013.12.005
Alves FA, Coracin FL, Gasparetto PF, Correa MEP. Oral complications of antineoplastic chemotherapy. JBC J Bras Clin Odontol Integr. 2003;7(40):337-40.
Lalla RV, Brennan MT, Gordon SM, et al. Oral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation Therapy. J Natl Cancer Inst Monogr. 2019;2019(53):lgz011. PMID: 31425601; https://doi.org/10.1093/jncimonographs/lgz011
Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003;39(2):91-100. PMID: 12509961; https://doi.org/10.1016/s1368-8375(02)00033-7
Damascena LCL, de Lucena NNN, Ribeiro ILA, et al. Severe Oral Mucositis in Pediatric Cancer Patients: Survival Analysis and Predictive Factors. Int J Environ Res Public Health. 2020;17(4):1235. PMID: 32075075; https://doi.org/10.3390/ijerph17041235
Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J. 2001;18(3):205-7. PMID: 11354213; https://doi.org/10.1136/emj.18.3.205
World Health Organization. WHO handbook for reporting results of cancer treatment. 48th ed. Geneva: WHO; 1979.
Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol. 2007;5(5):231-5. PMID: 17564153.
Prendergast V, Kleiman C, King M. The Bedside Oral Exam and the Barrow Oral Care Protocol: translating evidence-based oral care into practice. Intensive Crit Care Nurs. 2013;29(5):282-90. PMID: 23702324; https://doi.org/10.1016/j.iccn.2013.04.001
Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003;98(7):1531-9. PMID: 14508842; https://doi.org/10.1002/cncr.11671
Santos PS, Coracin FL, Barros JC, et al. Impact of oral care prior to HSCT on the severity and clinical outcomes of oral mucositis. Clin Transplant. 2011;25(2):325-8. PMID: 20482562; https://doi.org/10.1111/j.1399-0012.2010.01283.x
Jehn P, Stier R, Tavassol F, et al. Physical and Psychological Impairments Associated with Mucositis after Oral Cancer Treatment and Their Impact on Quality of Life. Oncol Res Treat. 2019;42(6):342-9. PMID: 30970370; https://doi.org/10.1159/000499720
Kim JW, Cha Y, Kim SJ, et al. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. Support Care Cancer. 2012;20(2):395-403. PMID: 21390568; https://doi.org/10.1007/s00520-011-1126-8
Raber-Durlacher JE, Weijl NI, Abu Saris M, et al. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer. 2000;8(5):366-71. PMID: 10975685; https://doi.org/10.1007/s005200050004 Erratum in: Support Care Cancer. 2001;9(2):135.
Nishimura N, Nakano K, Ueda K, et al. Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Support Care Cancer. 2012;20(9):2053-9. PMID: 22116139; https://doi.org/10.1007/s00520-011-1314-6
Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(9 Suppl):1995-2025. PMID: 15108222; https://doi.org/10.1002/cncr.20162
Palappallil DS, Nair BL, Jayakumar KL, Puvathalil RT. Comparative study of the toxicity of 5-fluorouracil-adriamycin-cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast. Indian J Cancer. 2011;48(1):68-73. PMID: 21248442; https://doi.org/10.4103/0019-509X.75836
Antuniassi AR. Occurrence and degree of severity of oral mucositis in relation to the salivary flow of patients undergoing chemotherapy [dissertation]. São Paulo: Faculdade de Odontologia da Universidade de São Paulo; 2005.
McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol. 1998;34(6):484-90. PMID: 9930359; https://doi.org/10.1016/s1368-8375(98)00068-2
Jensen SB, Vissink A, Limesand KH, Reyland ME. Salivary Gland Hypofunction and Xerostomia in Head and Neck Radiation Patients. J Natl Cancer Inst Monogr. 2019;2019(53):lgz016. PMID: 31425600; https://doi.org/10.1093/jncimonographs/lgz016
Epstein JB, Tsang AH, Warkentin D, Ship JA. The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94(1):39-44. PMID: 12193891; https://doi.org/10.1067/moe.2002.126018
Coracin FL, Santos PS, Gallottini MH, et al. Oral health as a predictive factor for oral mucositis. Clinics (Sao Paulo). 2013;68(6):792-6. PMID: 23778491; https://doi.org/10.6061/clinics/2013(06)11
Gandhi K, Datta G, Ahuja S, Saxena T, G Datta A. Prevalence of Oral Complications occurring in a Population of Pediatric Cancer Patients receiving Chemotherapy. Int J Clin Pediatr Dent. 2017;10(2):166-71. PMID: 28890617; https://doi.org/10.5005/iD-iournals-10005-1428
Allen G, Logan R, Revesz T, Keefe D, Gue S. The Prevalence and Investigation of Risk Factors of Oral Mucositis in a Pediatric Oncology Inpatient Population; a Prospective Study. J Pediatr Hematol Oncol. 2018;40(1):15-21. PMID: 29045267; https://doi.org/10.1097/MPH.0000000000000970
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
